Shifamed portfolio company Adona Medical today announced the introduction of its next-generation heart failure platform.
Brian Fahey, Adona Medical co-founder and CEO, unveiled the developing interatrial shunt technology in a presentation at the CSI Frankfurt 2023 conference.
The Adona heart failure management platform features an adjustable interatrial shunt with integrated bi-atrial pressure monitoring. Its shunt flow channel offers an adaptable geometry capable of growing larger or minimizing at any time post-implant. This can help optimize shunting flow or dose for patient needs at the time of the initial procedure. It then can adjust as the patient’s condition evolves over time.
Integrated sensors capture pressure readings from both the left and right atria multiple times per day. These sensors don’t require patient interaction, Adona says. Daily readings from the sensors help give physicians a more complete understanding of a patient’s hemodynamic status. They also augment shunt therapy by enabling more informed pharmaceutical management, according to a news release.
“Adona Medical is committed to providing heart failure patients and physicians with technologies that address the shortcomings of currently available solutions,” said Fahey. “You’d struggle to find a physician comfortable with deciding on a fixed dose of medication for a patient and never being able to alter it in the future or monitor its effects, but this is comparable to the use case for interatrial shunts currently under clinical investigation. At Adona, we believe that patient care can be pushed forward by a customizable and adjustable shunting approach combined with an advanced hemodynamic monitoring solution.”
Medical Design & Outsourcing: Shunt device startup Adona Medical wants to break barriers in nitinol and heart sensing
